NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) Monday announced that the
European Commission has granted marketing authorization for Emblaveo for the
treatment of adult patients impacted by serious infectious diseases.

The authorization is for complicated intra-abdominal infections,
hospital-acquired pneumonia, and complicated urinary tract infections, including
pyelonephritis. This approval is based on results from the previously reported
Phase 3 program comprising the REVISIT and ASSEMBLE studies.

The company said Emblaveo is also indicated for the treatment of infections due
to aerobic Gram-negative organisms in adult patients with limited treatment
options.

The marketing authorization of Emblaveo is valid in all 27 European Union member
states, as well as in Iceland, Liechtenstein, and Norway.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX